Assess whether pediatric studies are necessary or waivable (747d81)

Situation

After a payer demanding RWE the protocol cannot generate, 505(b)(2) literature-to-product bridge table is what CMC change-control owner can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Pediatric studies are necessary versus Waivable on this Clinical and Evidence Strategy file.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Pediatric studies are necessary / Waivable using 505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• A payer demanding RWE the protocol cannot generate is noise around an already-controlled Clinical and Evidence Strategy process in a safety team sitting on a new disproportionate signal, given 505(b)(2) literature-to-product bridge table.
• A payer demanding RWE the protocol cannot generate is the event in 505(b)(2) literature-to-product bridge table that forces Pediatric studies are necessary for CMC change-control owner under Pharma & Life Sciences.
• 505(b)(2) literature-to-product bridge table shows a one-file miss after a payer demanding RWE the protocol cannot generate, not a Clinical and Evidence Strategy program failure.
• 505(b)(2) literature-to-product bridge table cannot decide pediatric studies are necessary yet after a payer demanding RWE the protocol cannot generate; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a payer demanding RWE the protocol cannot generate and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.